Optimizing the Pharmacotherapy of Vascular Surgery Patients at Hospital Admission, at Discharge and at Post-discharge Check-up: Quasi-experimental Clinical Uncontrolled Trial (PHAROS)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 105
- 试验地点
- 1
- 主要终点
- Change in prevalence rate of drug related problems
研究概览
简要总结
This project aims to assess the impact of pharmaceutical care in collaboration with physicians on prevalence of DRPs at hospital admission and discharge in patients with carotid artery disease or lower extermity artery disease hospitalized at the Department of Vascular Surgery.
The key focus area of this project will be the identification of DRPs, their occurrence and type. As a part of further research, the investigators want to analyze the a) acceptance rate of pharmaceutical intervention by physicians. Proportion of accepted interventions by physicians was calculated and b) patients' understanding of his/her pharmacotherapy assessed on a three-point scale at hospital admission.
Hypothesis:
Null hypothesis: Pharmaceutical care provided at hospital admission and at hospital discharge does not reduce prevalence rates of DRPs in patients with carotid artery disease or lower extermity artery disease hospitalized at the Department of Vascular Surgery.
Alternative hypothesis: Pharmaceutical care provided at hospital admission and at hospital discharge reduces prevalence rates of DRPs in patients with carotid artery disease or lower extermity artery disease hospitalized at the Department of Vascular Surgery.
Primary outcomes:
Change in the prevalence rate of DRPs at hospital admission vs. hospital discharge.
Secondary outcomes:
- acceptance rate of pharmaceutical intervention by physician
- patients' understanding of his/her pharmacotherapy
详细描述
Medication reconciliation, medication review and patient education performed by a trained pharmacist in two timepoints.
All comments with a proposal from the pharmacist will be recorded in written together with a record of the therapy, entered in the patient's medical record and communicated with the physician.
Timepoints for intervention:
- At hospital admission
The patient is normally admitted to the planned hospitalization by the physician in cooperation with the nurse as described above. If the patient is over 18 years of age, takes more than three medicines, speaks and understands Slovak language and has signed an informed consent to participate in biomedical research, after being placed in a bed, a pharmacist comes to the patient and performs MR. During MR, the pharmacist creates a record of the patient's therapy (MR form for admission - attachment No. 2), the original of which is placed in the patient's medical record, and a copy is placed to pharmacist´s records.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years at the date of admission for hospitalization
- •patients taking at least 3 medications
- •patients with carotid artery disease or lower extremity artery disease
排除标准
- •Acute patients.Due to the urgent health condition, medication reconciliation is not the priority in these patients, furthermore, rendering the BPMH collection impossible.
- •Patients transferred from other hospitals/wards
- •Not willing to sign the informed consent form for the study
- •Not understanding Slovak language
- •Presence of any mental disorder affecting memory and recall ability (such as Alzheimer's disease)
- •Any other reason at the discretion of the investigator why he/she deems the participant not eligible for study participation (all such reasons will be recorded)
- •Participation in another clinical study
- •Furthermore, patients transferred to other hospitals/wards will be excluded from the study.
结局指标
主要结局
Change in prevalence rate of drug related problems
时间窗: through study completion, an average of 1 year
Change in the prevalence rate of drug related problems at a) hospital admission vs. hospital discharge, b) hospital discharge vs. post-discharge check-up.
次要结局
- patients characteristics(through study completion, an average of 1 year)
- Medication characteristics(through study completion, an average of 1 year)
研究者
Slavka Porubcova, PharmDr.
Principal Investigator
National Institute of Cardiovascular Diseases, Slovakia